Antibiotic resistance in cancer patients

References

• Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-10
   PubMed Web of Science ®Google Scholar
• Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. Am J Med 1977;62:731-42
   PubMed Web of Science ®Google Scholar
• Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4
   PubMed Web of Science ®Google Scholar
• Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39(Suppl 1)):S25-31
   Google Scholar
• Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36:149-58
   PubMed Web of Science ®Google Scholar
• Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013;19:474-9
   PubMed Web of Science ®Google Scholar
• Samonis G, Vardakas KZ, Maraki S, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 2013;21:2521-6
   PubMed Web of Science ®Google Scholar
• Montassier E, Batard E, Gastinne T, et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013;32:841-50
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079-81
   PubMed Web of Science ®Google Scholar
• Bodro M, Gudiol C, Garcia-Vidal C, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer 2014;22:603-10
   PubMed Web of Science ®Google Scholar
• Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011;24:545-53
   PubMed Web of Science ®Google Scholar
• Carratalà J, Fernández-Sevilla A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1240-1
   PubMed Web of Science ®Google Scholar
• Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681-7
   PubMed Web of Science ®Google Scholar
• Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011;15:e277-81
   PubMed Web of Science ®Google Scholar
• Kang CI, Song JH, Chung DR, et al. On behalf of the Korean Network for Study on Infectious Diseases (KONSID). Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer 2012;20:2371-8
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 2012;91:1299-304
   PubMed Web of Science ®Google Scholar
• Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 2014;42:5-13
   PubMed Web of Science ®Google Scholar
• Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003;37:1144-5
   PubMed Web of Science ®Google Scholar
• Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol 2013;92:533-41
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009;58:299-307
   PubMed Web of Science ®Google Scholar
• Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012;91:115-21
   PubMed Web of Science ®Google Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010;65:333-41
   PubMed Web of Science ®Google Scholar
• Cornejo-Juárez P, Pérez-Jiménez C, Silva-Sánchez J, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One 2012;7:e35780
   PubMed Web of Science ®Google Scholar
• Huh K, Kang CI, Kim J, et al. Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer. Diagn Microbiol Infect Dis 2014;78:172-7
   PubMed Web of Science ®Google Scholar
• Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011;66:657-63
   PubMed Web of Science ®Google Scholar
• Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res 2009;42:89-93
   Google Scholar
• Oliveira AL, Souza M, Carvalho-Dias VM, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007;39:775-81
   PubMed Web of Science ®Google Scholar
• Caselli D, Cesaro S, Ziino O, et al. Multidrug-resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010;95:1612-15
   PubMed Web of Science ®Google Scholar
• Johnson LE, D’Agata EM, Paterson DL, et al. Pseudomonas aerugionsa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009;11:227-34
   PubMed Web of Science ®Google Scholar
• Trecarich EM, Tumbarello M, Caira M, et al. Multidrug resistant pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011;96:e1-3
   PubMedGoogle Scholar
• Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 2012;91:1299-304
   PubMed Web of Science ®Google Scholar
• Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimcrob Chemother 2001;47:247-50
   PubMed Web of Science ®Google Scholar
• Patel G, Bonomo RA. ‘‘Stormy waters ahead’’: global emergence of carbapenemases. Front Microbiol 2013;4:48
   PubMed Web of Science ®Google Scholar
• Pillai DR, Mc Geer A, Low DE. New Delhi metallo-b-lactamase-1 in Enterobacteriaceae: emerging resistance. CMAJ 2011;183:59-64
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009;63:427-37
   PubMed Web of Science ®Google Scholar
• Glasner C, Albiger B, Buist G, et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013;18
   PubMedGoogle Scholar
• Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012;73:354-60
   PubMed Web of Science ®Google Scholar
• Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106
   PubMed Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012;4:148ra116
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 2013;54:799-806
   PubMed Web of Science ®Google Scholar
• Ansari SR, Hanna H, Hachem R, et al. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007;109:2615-22
   PubMed Web of Science ®Google Scholar
• Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007;45:1602-9
   PubMed Web of Science ®Google Scholar
• Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009;73:355-63
   PubMed Web of Science ®Google Scholar
• Fukuta Y, Robert R, Muder MD, et al. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infec Control 2013;41:1249-52
   PubMed Web of Science ®Google Scholar
• Sood P, Seth T, Kapil A, et al. Emergence of multidrug resistant Acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc 2012;110:439-44
   PubMedGoogle Scholar
• Irfan S, Idrees F, Mehraj V, et al. Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008;8:80
   PubMedGoogle Scholar
• Arias C, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;10:266-78
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-38
   PubMed Web of Science ®Google Scholar
• Schouten MA, Voss A, Hoogkamp-Korstanje JA, The European VRE. Study Group. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob Agents Chemother 1999;43:2542-6
   PubMedGoogle Scholar
• Hsueh PR, Chen WH, Teng LJ, et al. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26:43-9
   PubMed Web of Science ®Google Scholar
• Top J, Willems R, van der Velden S, et al. Emergence of clonal complex 17 Enterococcus faecium in the Netherlands. J Clin Microbiol 2008;46:214-19
   PubMed Web of Science ®Google Scholar
• Willems RJL, van Schaik W. Transition of Enterococcus faecium from commensal organism to nosocomial pathogen. Future Microbiol 2009;4:1125-35
   PubMedGoogle Scholar
• Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 2010;16:1576-81
   PubMed Web of Science ®Google Scholar
• Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007;79:226-33
   PubMed Web of Science ®Google Scholar
• Kapur D, Dorsky D, Feingold JM, et al. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:147-52
   PubMed Web of Science ®Google Scholar
• Ghanem G, Hachem R, Jiang Y, et al. Outcomes for and risk factors associated with vancomycin‐resistant Enterococcus faecalis and vancomycin‐resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 2007;28:1054-9
   PubMedGoogle Scholar
• Gudiol C, Ayats J, Camoez M, et al. Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium in cancer patients: risk factors, molecular epidemiology and outcomes. PLoS One 2013;8(9):e74734
   PubMed Web of Science ®Google Scholar
• Jones RN. Contemporary antimicrobial susceptibility pattern of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999;29:495-502
   PubMed Web of Science ®Google Scholar
• González-Barca E, Carratalà J, Mykietiuk A, et al. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 2001;20:117-19
   PubMed Web of Science ®Google Scholar
• El Zakhem A, Chaftari AM, Bahu R, et al. Central line-associated bloodstream infections caused by Staphylococcus aureus in cancer patients: clinical outcome and management. Ann Med 2014;46(3):163-8
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
   PubMed Web of Science ®Google Scholar
• de Kraker ME, Jarlier V, Monen JC, et al. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013;19:860-8
   PubMed Web of Science ®Google Scholar
• Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010;304:641-8
   PubMed Web of Science ®Google Scholar
• Mahajan S, Shah JN, Hachem R, et al. Characteristics and Outcomes of Methicillin-Resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 2012;17:1329-36
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Wunderink RG, Postelnick MJ, et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006;26:539-50
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5
   PubMed Web of Science ®Google Scholar
• Diaz-Granados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005;191:588-95
   PubMedGoogle Scholar
• Dubberke ER, Hollands JM, Georgantopoulos P, et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 2006;38:813-19
   PubMed Web of Science ®Google Scholar
• Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008;52:1413-18
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51
   PubMed Web of Science ®Google Scholar
• Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus betalactam. aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003;CD003038
   Google Scholar
• Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001–2002). Diagn Microbiol Infect Dis 2003;47:435-40
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98:1826-35
   PubMed Web of Science ®Google Scholar
• Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43:447-59
   PubMed Web of Science ®Google Scholar
• Glasmacher A, von Lilienfeld-Toal M, Schulte S, et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11(Suppl 5):17-23
   PubMedGoogle Scholar
• Souli M, Galani I, Boukovalas S, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011;55:2395-7
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17:1135-41
   PubMed Web of Science ®Google Scholar
• Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009;53:1868-73
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119-25
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31
   PubMed Web of Science ®Google Scholar
• Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597-607
   PubMed Web of Science ®Google Scholar
• Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003;14:795-801
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:6-64
   Google Scholar
• Raad I, Bompart F, Hachem F. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999;18:199-202
   PubMed Web of Science ®Google Scholar
• Rolston KV, McConnell SA, Brown J, Lamp KC. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol 2010;8:249-56. 90
   PubMedGoogle Scholar
• Poutsiaka DD, Skiffington S, Miller KB, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54:567-71
   PubMed Web of Science ®Google Scholar
• Chemaly Rf, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 2009;88:211-20
   PubMed Web of Science ®Google Scholar
• Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. J Crit Care Med 2009;37:2071-8
   Google Scholar
• Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011;15:R206
   PubMed Web of Science ®Google Scholar
• Abbott IJ, Roberts JA. Infusional β-lactam antibiotics in febrile neutropenia: has the time come? Curr Opin Infect Dis 2012;25:619-25
   PubMedGoogle Scholar
• Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005;49:3550-3
   PubMed Web of Science ®Google Scholar
• Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010;44:929-35
   PubMed Web of Science ®Google Scholar
• Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332-9
   PubMed Web of Science ®Google Scholar
• Gyssens IC, Kern WV, Livermore DM; on behalf of ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 2013;98:1821-5
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy 2012;32:722-34
   PubMed Web of Science ®Google Scholar
• Shaikh ZH, Osting CA, Hanna HA, et al. Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre. J Hosp Infect 2002;51:52-8
   PubMedGoogle Scholar
• Craig M, Cumpston AD, Hobbs GR, et al. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 2007;39:477-82
   PubMed Web of Science ®Google Scholar
• Dominguez EA, Smith TL, Reed E, et al. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000;21(Suppl 1):S4-8
   Google Scholar
• Hashino S, Morita L, Kanamori H, et al. Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancy. Eur J Clin Microbiol Infect Dis 2012;31:173-8
   PubMed Web of Science ®Google Scholar
• Cumpston A, Craig M, Hamadani M, et al. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. Transpl Infect Dis 2013;15:142-9
   PubMed Web of Science ®Google Scholar
• Chong Y, Shimoda S, Yakushiji H, et al. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. PLoS One 2013;8:e54190
   Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014;20(Suppl 1):1-55
   PubMed Web of Science ®Google Scholar
• WHO Guidelines on Hand Hygiene in Health Care. Available from: http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf
   Google Scholar
• Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000;356:1307-12
   PubMed Web of Science ®Google Scholar
• Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J 2007;9:424-9
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Dakdouki GK, El-Chammas KI, et al. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int J Infec Dis 2007;11:450-3
   PubMedGoogle Scholar
• Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30(Suppl 1):S51-9
   PubMed Web of Science ®Google Scholar
• Chen CY, Tsay W, Tang JL, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 2010;138:1044-51
   PubMed Web of Science ®Google Scholar
• Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011;15:e277-81
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 2012;91:1299-304
   PubMed Web of Science ®Google Scholar
• Kjellander C, Björkholm M, Cherif H, et al. Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 2012;88:422-30
   PubMed Web of Science ®Google Scholar
• Ariffin H, Navaratnam P, Mohamed M, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000;4:21-5
   PubMedGoogle Scholar
• Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010;116:967-73
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007;13:615-21
   PubMed Web of Science ®Google Scholar